EMA Accepts Genzyme MAA of Multiple Sclerosis Drug

The European Medicines Agency has accepted the Genzyme’s filing of the MAA for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Pharmaceutical Business Review